Valuation: CureVac N.V.

Capitalization 1.06B 1.22B 1B 909M 1.68B 106B 1.9B 11.85B 4.54B 48.6B 4.6B 4.5B 179B P/E ratio 2025 *
-10.4x
P/E ratio 2026 * -9.68x
Enterprise value 703M 810M 662M 602M 1.11B 70.18B 1.25B 7.84B 3B 32.15B 3.04B 2.98B 118B EV / Sales 2025 *
10.2x
EV / Sales 2026 * 8.8x
Free-Float
54.74%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.91%
1 week-2.33%
Current month+21.70%
1 month+39.49%
3 months+88.24%
6 months+89.55%
Current year+59.53%
More quotes
1 week 5.41
Extreme 5.41
5.58
1 month 4
Extreme 4
5.72
Current year 2.48
Extreme 2.475
5.72
1 year 2.37
Extreme 2.37
5.72
3 years 2.22
Extreme 2.215
15.62
5 years 2.22
Extreme 2.215
151.8
10 years 2.22
Extreme 2.215
151.8
More quotes
Manager TitleAgeSince
Chief Executive Officer 55 2023-03-27
Director of Finance/CFO 58 2024-11-10
Chief Operating Officer 60 2021-06-30
Director TitleAgeSince
Chairman 74 2015-07-31
Director/Board Member 59 2015-07-31
Director/Board Member 59 2019-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.91%-2.33%+66.87%-61.64% 1.22B
+0.39%-1.51%+17.39%+14.44% 48.43B
-2.25%-8.36%+58.27%+61.84% 29.32B
+0.08%-1.38%-28.45%-22.16% 26.77B
+1.25%+0.87%+0.01%+19.62% 26.16B
-40.00%+142.71%+35,996.87%+3,366.80% 18.8B
+0.10%-1.36%+12.82%-18.13% 12.32B
-1.14%-4.17%+138.51% - 11.83B
+2.02%+0.56%-54.05%-28.64% 11.64B
+3.63%+3.57%+38.37%+106.90% 10.68B
Average -3.68%+12.80%+3,624.66%+382.11% 19.72B
Weighted average by Cap. -3.63%+11.71%+3,449.14%+357.32%
See all sector performances

Financials

2025 *2026 *
Net sales 69.05M 79.61M 65.04M 59.1M 109M 6.89B 123M 770M 295M 3.16B 299M 292M 11.61B 85.64M 98.73M 80.67M 73.3M 136M 8.55B 153M 955M 366M 3.92B 370M 363M 14.4B
Net income -103M -119M -97.11M -88.23M -163M -10.29B -184M -1.15B -440M -4.72B -446M -436M -17.33B -112M -129M -106M -95.94M -177M -11.19B -200M -1.25B -479M -5.13B -485M -475M -18.85B
Net Debt -360M -415M -339M -308M -570M -35.92B -642M -4.01B -1.54B -16.45B -1.56B -1.52B -60.48B -309M -356M -291M -264M -489M -30.83B -551M -3.44B -1.32B -14.13B -1.34B -1.31B -51.92B
More financial data * Estimated data
Logo CureVac N.V.
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Employees
904
More about the company
Date Price Change Volume
25-06-20 5.440 $ -0.91% 2,043,914
25-06-18 5.490 $ -0.18% 1,007,741
25-06-17 5.500 $ -0.36% 1,459,832
25-06-16 5.520 $ -0.90% 1,501,011
25-06-13 5.570 $ -0.54% 4,834,936

Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.719EUR
Average target price
5.145EUR
Spread / Average Target
+9.03%
Consensus

Quarterly revenue - Rate of surprise